Key result
IV vernakalant induces atrial flutter with 1:1 AV conduction in recent-onset AF.
Why the study?
Vernakalant is used for cardioversion of recent onset atrial fibrillation with low pro-arrhythmic risk, but rare cases of atrial flutter with 1 : 1 AV conduction have not been well described.
Case Report (n=1)
Intravenous vernakalant can induce atrial flutter with 1:1 atrioventricular conduction in patients with structurally normal hearts, necessitating careful monitoring during administration.
Answers are grounded in this paper and cite their sources.
May necessitate closer monitoring during vernakalant use; leaves open the incidence of this complication.
A 44-year-old healthy woman presented with a first episode of recent onset atrial fibrillation (Panel A). Intravenous vernakalant was administered. Organization to atrial flutter with 2 : 1 atrioventricular conduction occurred (Panel B). After completion of the second infusion, the atrial cycle length prolonged slightly resulting in 1 : 1 atrioventricular conduction (Panel C). Immediate electrical cardioversion was performed. Diagnostic work-up did not reveal any structural or electrical pathology of the heart. Vernakalant is a newer, relatively atrial-selective antiarrhythmic drug, designed to overcome the safety issues of the currently available drugs for cardioversion of atrial fibrillation. The conversion rate in recent onset atrial fibrillation is reported to be ∼50%. Compared with other antiarrhythmic drugs, vernakalant was not associated with rapid conducted atrial flutter or serious ventricular arrhythmias. The guidelines recommend vernakalant for cardioversion of recent onset atrial fibrillation in patients with no or minimal structural heart disease and with some restrictions in patients with moderate heart disease. This case describes the occurrence of atrial flutter with 1 : 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation in a patient with a structural normal heart and no evidence of pre-existing arrhythmias. Therefore, despite the low pro-arrhythmic risk, careful patient monitoring is necessary when using vernakalant. The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/Documents/atrial-flutter-with-atrioventricular.pdf.
No takes yet. Share an insight, caveat, or question.
Franzini et al. (2013) conducted a case report in Recent onset atrial fibrillation (n=1). Vernakalant was evaluated on Atrial flutter with 1:1 atrioventricular conduction. Intravenous vernakalant for recent onset atrial fibrillation induced atrial flutter with 1:1 atrioventricular conduction in a patient with a structurally normal heart.
Synapse has enriched 10 related papers. Consider them for comparative context: